| Year | Title | Author(s) |
| 2024 |
Targeting the ribosome to treat multiple myeloma
Molecular Therapy Oncology |
Maclachlan, KH Gitareja, K Kang, J Cuddihy, A Cao, YX Hein, N Cullinane, C Ang, CS Brajanovski, N Pearson, RB Khot, A Sanij, E Hannan, RD Poortinga, G Harrison, SJ |
| 2021 |
CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition
Molecular Cancer Therapeutics |
Lawrence, MG Porter, LH Choo, N Pook, D Grummet, JP Pezaro, CJ Sandhu, S Ramm, S Luu, J Bakshi, A Goode, DL Sanij, E Pearson, RB Hannan, RD Simpson, KJ Taylor, RA Risbridger, GP Furic, L |
| 2020 |
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
Nature Communications |
Sanij, E Hannan, KM Xuan, JC Yan, SF Ahern, JE Trigos, AS Brajanovski, N Son, J Chan, KT Kondrashova, O Lieschke, E Wakefield, MJ Frank, D Ellis, S Cullinane, C Kang, J Poortinga, G Nag, P Deans, AJ Khanna, KK Mileshkin, L McArthur, GA Soong, J Berns, EMJJ Hannan, RD Scott, CL Sheppard, KE Pearson, RB |